Clinical Trial Update: Cannabidiol Usage as an Adjunct Therapy for Crohn's Disease [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial investigating cannabidiol as an adjunct therapy for Crohn's disease (Phase 2/Phase 3) has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Inflammatory Bowel Disease

Drugs mentioned

• Cannabidiol (cannabidiol)

Snippet

Sponsor: University of Illinois at Chicago | Conditions: Crohn Disease, Inflammatory Bowel Diseases | Phase 2, Phase 3 | Status: WITHDRAWN